MIT researchers have developed a battery-free, subcellular-sized device made of polymer designed to measure and modulate a neuron’s electrical and metabolic activity. When the device is activated by light, it can gently wrap around the neuron cell’s axons and dendrites without damaging the cells.

Scientists want to inject thousands of these tiny wireless devices into a patient’s central nervous system and then actuate them noninvasively using light. The light would penetrate the tissue and allow precise control of the devices, and thereby restore function in cases of neuronal degradation like multiple sclerosis (MS).

The MIT researchers developed these thin-film devices from a azobenzene, a soft polymer that readily reacts to light. Thin sheets of azobenzene roll into a cylinder when exposed to light, which enables them to wrap around cells. Researchers can control the direction and diameter of the rolling by changing the intensity and polarization of the light, producing a microtube with a diameter smaller than one micrometer.

RegenxBio, a publicly-traded biotech firm, released data this week from a Phase 2 clinical trial designed to test its leading genetic therapy product in patients with bilateral wet age-related macular degeneration (AMD). AMD is characterized by abnormal growth of blood vessels in the retina, and is a leading cause of loss of vision in elderly populations globally.

ABBV-RGX-314, developed in collaboration with AbbVie, offers the potential of a one-time treatment for wet AMD and other retinal conditions, including diabetic retinopathy. This is in contrast to existing treatments which rely on repeated intraocular injections of drugs that inhibit a protein known as Vascular Endothelial Growth Factor (VEGF), a protein responsible for the formation of new retinal blood vessels.

The ABBV-RGX-314 therapy is based on a an AAV8 viral vector as a delivery system. The AAV8 platform has been genetically engineered to encode an antibody that can inhibit VEGF for the long-term.